Establishing Clinical Utility of a New Diagnostic Test in Patients Undergoing Cardiac Catheterization

NACompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

June 1, 2020

Study Completion Date

June 30, 2020

Conditions
AKIContrast-induced Nephropathy
Interventions
OTHER

Experimental Arm

"First, these providers will receive educational materials (e.g. a slide deck and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the Hikari DX L-FABP test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the L-FABP test at the clinically-appropriate point in each case."

Trial Locations (1)

94133

QURE Healthcare, San Francisco

All Listed Sponsors
collaborator

Hikari DX

UNKNOWN

lead

Qure Healthcare, LLC

INDUSTRY

NCT04266834 - Establishing Clinical Utility of a New Diagnostic Test in Patients Undergoing Cardiac Catheterization | Biotech Hunter | Biotech Hunter